Ying He1, Wandi Zheng1. 1. Department of Infectious Diseases, The First People's Hospital of Fuyang Hangzhou Hangzhou 311400, Zhejiang, China.
Abstract
OBJECTIVE: To investigate the efficacy of systemic care combined with thymopentin and 2HRZE/4HR in the treatment of primary tuberculosis. METHODS: The clinical data of 93 patients with primary tuberculosis were retrospectively collected and divided into two groups based on the intervention method. Group A (n=46) was treated only with 2HRZE/4HR, and group B (n=47) was treated with the 2HRZE/4HR combined with thymopentin. Meanwhile, both groups received systematic care. The lesion absorption rate, sputum conversion rate (SCR), T lymphocyte subpopulation count, immunoglobulin level, lung function index, changes in sputum supernatant levels of cytokines before and after treatment, and the occurrence of adverse reactions were compared. RESULTS: Group B exhibited higher complete absorption rate of foci and lower basic absorption rate than group A (P < 0.05). The SCRs of group B after 2, 4 and 6 months of intervention were higher than those of group A (P < 0.05). Compared with group A, group B had lower CD8+ level and higher CD4+ and CD3+ levels (P < 0.05). Group B also had higher levels of IgA, IgG, and IgM than group A after intervention (P < 0.05). Group B had higher levels of FEV1, PEF, and FVC than group A after intervention (P < 0.05). In contrast to group A, group B had lower IL-4 levels and higher TNF-γ levels (P < 0.05). The incidence rate of adverse events in group B was not significantly different from that in group A (P > 0.05). CONCLUSION: Systemic care combined with 2HRZE/4HR was effective for treatment of primary tuberculosis, which is beneficial for improving the immunity, SCR, and the inflammatory status, with low incidence of adverse events and a high safety level. AJTR
OBJECTIVE: To investigate the efficacy of systemic care combined with thymopentin and 2HRZE/4HR in the treatment of primary tuberculosis. METHODS: The clinical data of 93 patients with primary tuberculosis were retrospectively collected and divided into two groups based on the intervention method. Group A (n=46) was treated only with 2HRZE/4HR, and group B (n=47) was treated with the 2HRZE/4HR combined with thymopentin. Meanwhile, both groups received systematic care. The lesion absorption rate, sputum conversion rate (SCR), T lymphocyte subpopulation count, immunoglobulin level, lung function index, changes in sputum supernatant levels of cytokines before and after treatment, and the occurrence of adverse reactions were compared. RESULTS: Group B exhibited higher complete absorption rate of foci and lower basic absorption rate than group A (P < 0.05). The SCRs of group B after 2, 4 and 6 months of intervention were higher than those of group A (P < 0.05). Compared with group A, group B had lower CD8+ level and higher CD4+ and CD3+ levels (P < 0.05). Group B also had higher levels of IgA, IgG, and IgM than group A after intervention (P < 0.05). Group B had higher levels of FEV1, PEF, and FVC than group A after intervention (P < 0.05). In contrast to group A, group B had lower IL-4 levels and higher TNF-γ levels (P < 0.05). The incidence rate of adverse events in group B was not significantly different from that in group A (P > 0.05). CONCLUSION: Systemic care combined with 2HRZE/4HR was effective for treatment of primary tuberculosis, which is beneficial for improving the immunity, SCR, and the inflammatory status, with low incidence of adverse events and a high safety level. AJTR